Shanghai Kehua Bio-engineering (KHB) has obtained an EU class D in vitro diagnostic regulation certification for rapid tests covering the company’s diagnostic kit for HIV (1/2) antibody (Colloidal Gold) V2.
KHB’s HIV diagnostic kit tests for human immunodeficiency virus (HIV)-1 and -2 antibodies in human serum, plasma, venous and capillary whole blood.
There has been a rise in the number of diagnostics available for HIV testing. As per a GlobalData market model, the global HIV testing market in 2022 was worth $1.8bn and that is predicted to rise to $2.4bn in 2033, growing at a CAGR of 1.5%. The self-testing sub-market is expected to be worth around $500m by 2027.
